NUS’ 2Q26 results reflected a weaker near-term operating setup, with revenue of $320.1M below our $345.2M estimate as Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y, respectively. Management reduced FY26 revenue guidance to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90, while pushing the India launch into 1H27 as it refines local sourcing, logistics, technology integration, and the affiliate model. Prysm iO remains the primary longer-term growth initiative, with more than 39,000 devices placed and 2.5M scans completed, though sustainable improvement will depend on better sales-force productivity and recruiting trends. The revised outlook lowers the near-term earnings bar, but Prysm iO adoption, cost optimization, and the East-West operating structure could improve the earnings profile into 2027.